vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimers disease and diabetes, today announced that it will deliver an oral presentation and present a poster at the 11th Clinical Trials on Alzheimers Disease (CTAD) conference on October 24-27, 2018 in Barcelona, Spain.
The oral presentation will detail the results from the phase 3 STEADFAST study of azeliragon in patients with mild Alzheimers disease. Details of the oral presentation are listed below:
Oral Presentation Title: Safety and efficacy results from the phase 3, multicenter, 18-month STEADFAST trial of azeliragon in patients with mild Alzheimers disease Date and Time: Fri., Oct. 26, 2018 at 3 p.m. CEST (9 a.m. EST)
In addition, a subgroup analysis from the companys STEADFAST trial will be presented as a poster. Details of the poster presentation are listed below:
Late-Breaking Poster Title: Is RAGE the missing link between diabetes and dementia? Results from a subgroup analysis of the STEADFAST trial Poster Number: LBP18 Category: Clinical Trials: Results Date and Time: Wed., Oct. 24, 2018 (3 p.m. CEST) through Sat., Oct. 27, 2018 (3 p.m. CEST)
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimers disease and diabetes as well as treatment of inflammatory disorders.
The STEADFAST study, two independent and identical randomized, double-blind, placebo-controlled Phase 3 trials (Part A and Part B), was designed to investigate the safety and efficacy of azeliragon as a potential treatment for patients with mild Alzheimers disease. The 18-month study targeted enrollment of 800 patients (400 in each trial). The first trial enrolled patients in the United States and Canada who had a clinical diagnosis of mild Alzheimers disease and an MRI consistent with this diagnosis. Enrollment of the second trial included study sites in the United Kingdom, Ireland, Australia, New Zealand and South Africa. In April 2018, results were announced that the Part A Study failed to meet either co-primary endpoint and clinical trials involving azeliragon, including the Part B Study and the open-label extension study were terminated, although the majority of patients in the Part B Study had at least 12 months worth of data at the time of closure. In June 2018, topline efficacy results from the Part B Study were announced showing that the study also failed to meet either of the co-primary endpoints.
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms anticipate, believe, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, will, would and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading Risk Factors in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.